Decrease in Paraoxonase Enzyme Level and Myocardial İnfarction

NCT ID: NCT04243876

Last Updated: 2022-05-31

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-12-30
• Study Completion Date: 2022-05-27

Brief Summary

Myocardial infarction is a polygenic disease that may occur due to various environmental risk factors. Mortality risk of the disease; sex, age, smoking, systolic blood pressure, total cholesterol, and high-density lipoprotein levels. The paraoxonase-1 phenotype is expressed as the paraoxonase/arylesterase ratio and is closely related to high-density lipoprotein, acting as an endogenous defense mechanism against vascular oxidative stress, thus contributing to the prevention of atherosclerosis. Serum concentration and activity depend on environmental factors as well as genetic polymorphism. This decrease in enzyme concentration causes changes in gene expression (1). Numerous data on Paraoxonase-1 levels have been found in studies, especially with decreasing serum paraoxonase and arylesterase activities with age, associated with increased risk of systemic oxidative stress and atherosclerosis in humans. Many studies have shown that serum Paraoxonase-1 activity is significantly reduced in people with myocardial infarction, dyslipidemia, atherosclerosis, and chronic kidney disease. The most important risk factor for these and similar diseases is aging. Diversity of conditions such as genetic predisposition, malnutrition, stress, and smoking, which increases vascular dysfunction due to oxidative stress, classify individuals with acute myocardial infarction according to age groups and investigate whether there is a relationship between serum Paraoxonase-1 activity and severity of coronary artery disease in young patients. The paraoxonase-1 enzyme, which is known to decrease blood levels with age, is found to be significantly lower in patients with myocardial infarction at a young age compared to the healthy control group.

Detailed Description

High-density lipoprotein (HDL), known as good cholesterol, is named because of its protective effects on the cardiovascular system. in order to summarize the mechanism of the event, cholesterol is transported from the liver to the cells and from the cells back to the liver via blood. Cholesterol and other fats are carried in packets called lipoprotein to dissolve in the blood. Those with these are two kinds of cholesterol, these low-density lipoproteins and good cholesterol can help to lower the cholesterol as well. LDL cholesterol is the main package that carries cholesterol in the blood. When the blood is high, it sticks to the inside of the veins and forms plaques around here. With the addition of cholesterol, a blood clot that formed in cracks that occur on these plaques grow the arteries and clogs them. If the blockage occurs in the heart vessels, it can cause a heart attack and stroke. Cholesterol in the blood is a part of a package called HDL-cholesterol is carried in. HDL-cholesterol prevents the accumulation of cholesterol in the veins.

It collects the cholesterol circulating in the blood and brings it to the liver to get rid of it from the body. Thus, it reduces the exposure of blood vessels to the harmful effects of cholesterol. All these effects of HDL cholesterol in the paraoxonase enzyme owes. This may be the reason why Dolat may even use another nomenclature instead of HDL in future years. A paraoxonase-1 enzyme, which is known to decrease blood level with age, is found to be significantly lower in patients with myocardial infarction at a young age compared with the healthy control group in this study, and the measurement of this enzyme level can be used as a screening test in people with risk factors.

Conditions

Myocardial Infarction; High-Density Lipoid Deficiency

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

paraoxanase

Enzyme level

paraoxanase enzyme level

Intervention Type: DIAGNOSTIC_TEST

presence of paraoxonase enzyme deficiency and associated troponin elevation

Myocardial infarction

RESULTS OF ANGIOGRAPHY

paraoxanase enzyme level

Intervention Type: DIAGNOSTIC_TEST

presence of paraoxonase enzyme deficiency and associated troponin elevation

Interventions

paraoxanase enzyme level

presence of paraoxonase enzyme deficiency and associated troponin elevation

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

troponin level; HDL level

Eligibility Criteria

Inclusion Criteria

• Those over the age of 18
• All acute coronary syndrome patients

Exclusion Criteria

• Patients with normal angiography

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bezmialem Vakif University

OTHER

Sponsor Role: lead

Responsible Party

Bahadir Taslidere

Associate Professor, clinical research

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

bahadir taslidere

Role: PRINCIPAL_INVESTIGATOR

BEZMİALEM VAKİF UNİVERSİTY

Locations

Bezmialem vakif university

Istanbul, Eyalet/Yerleşke, Turkey (Türkiye)

Countries

Turkey (Türkiye)

Provided Documents

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Other Identifiers

20/9

Identifier Type: -

Identifier Source: org_study_id